Day: January 14, 2025

H&R Block combines 70 years of trusted expertise with cutting-edge technology and unparalleled support to ensure hardworking Americans get every dollar they deserve at tax time KANSAS CITY, Mo., Jan. 14, 2025 (GLOBE NEWSWIRE) — With e-file set to open on Jan. 27, H&R Block (NYSE: HRB) is arming taxpayers with the latest information regarding significant changes to tax laws, deductions and credits that could impact individual returns, and the resources needed to minimize tax liabilities and receive their maximum refund – guaranteed. As the pioneer of the tax preparation category 70 years ago, H&R Block is trusted by more than 20 million hardworking Americans each year to ensure the best possible outcome at tax time with less stress by combining the latest technology that enables individuals to file how and when...

OLNEY, Md., Jan. 14, 2025 (GLOBE NEWSWIRE) — Sandy Spring Bancorp, Inc. (Nasdaq: SASR) will release its fourth quarter earnings for 2024 on Tuesday, January 28, 2025. About Sandy Spring Bancorp, Inc.Sandy Spring Bancorp, Inc., headquartered in Olney, Maryland, is the holding company for Sandy Spring Bank, a premier community bank in the Greater Washington, D.C. region. With over 50 locations, the bank offers a broad range of commercial and retail banking, mortgage, private banking, and trust services throughout Maryland, Virginia, and Washington, D.C. Through its subsidiaries, Rembert Pendleton Jackson  and West Financial Services, Inc., Sandy Spring Bank also offers a comprehensive menu of wealth management services. Source: Sandy Spring Bancorp, Inc. For additional information or questions, please contact:  Daniel J. Schrider,...

311 subjects enrolled across various stages of loading and randomization in SOL-R, Ocular’s second registrational trial of AXPAXLI™ in wet AMD, as of January 10, 2024 First wet AMD registrational trial, SOL-1, completed randomization in December 2024 with topline data anticipated in Q4 2025 Company plans to seek FDA feedback in H1 2025 on clinical trial design for AXPAXLI in NPDR BEDFORD, Mass., Jan. 14, 2025 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to redefining the retina experience, outlined exceptional clinical progress across its registrational program for AXPAXLI™ in wet age-related macular degeneration (wet AMD), plans to advance AXPAXLI in non-proliferative diabetic retinopathy (NPDR), and the Company’s strategic outlook for...

WILMINGTON, Del., Jan. 14, 2025 (GLOBE NEWSWIRE) — Ashland Inc. (NYSE: ASH) today announced plans to issue its first-quarter fiscal 2025 earnings release at approximately 5 p.m. ET on Tuesday, January 28, 2025. The company’s live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 9 a.m. ET on Wednesday, January 29. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://investor.ashland.com. Among those participating in the webcast presentation will be:Guillermo Novo, chair, and chief executive officer Kevin Willis, senior vice president and chief financial officer Dago Caceres, senior vice president, general manager, specialty additives Alessandra Faccin, senior vice president, general manager,...

KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25 Kymera plans to initiate a KT-621 Phase 1b trial in atopic dermatitis (AD) patients in 2Q25 with data in 4Q25 and plans to initiate parallel Phase 2b trials in AD and asthma in late 2025 and early 2026, respectively KT-295 (TYK2) to advance into Phase 1 testing in 2Q25 with data expected in late 2025 KT-474/SAR444656 (IRAK4) Phase 2b dose-ranging studies in hidradenitis suppurativa (HS) and AD ongoing, with completion expected in 1H26 and mid-2026, respectively Novel oral immunology program with a first-in-class development candidate to be disclosed in 1H25 Well-capitalized with $8501 million in cash and runway into mid-2027 Kymera to present its 2025 outlook at J.P. Morgan Annual Healthcare Conference onTuesday, January 14, 2025, at 9:00 a.m. PT/12:00...

Cemsidomide Data Presented at American Society of Hematology (ASH) Annual Meeting Support Best-in-Class Profile; Program Advancing to Next Phase of Clinical Development in Multiple Myeloma and Non-Hodgkin’s Lymphoma CFT1946 Phase 1 Trial Continues to Progress in BRAF V600X Solid Tumors With Monotherapy Dose Escalation Expected to Complete in 1H 2025; Data in Melanoma and Colorectal Cancer Expected in Second Half of 2025 CFT8919 Progressing Through Phase 1 Dose Escalation in Greater China; Phase 1 Data Will Inform Future Development Plans Outside of China Cash Runway Expected to Fund Operations Into 2027 WATERTOWN, Mass., Jan. 14, 2025 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced its anticipated...

VANCOUVER, British Columbia, Jan. 14, 2025 (GLOBE NEWSWIRE) — HydroGraph Clean Power Inc. (CSE: ‎HG) (OTCQB: HGCPF) (the “Company” or “HydroGraph”) a sustainable commercial manufacturer of pristine graphene, today announced that President & CEO Kjirstin Breure will participate in two upcoming investor conferences in January 2025. January 17- 19, 2025AlphaNorth Capital EventNassau, BahamasThe Company will host meetings with participating brokers and investors January 21-23, 2025Sequire Investor SummitSan Juan, Puerto RicoThe Company will host meetings with participating high-net, family office and institutional investors HydroGraph provides high purity, functional and specialized graphene products through a proprietary “explosion synthesis” process, which allows for exceptional purity, low energy use and identical batches....

PLAINVIEW, N.Y., Jan. 14, 2025 (GLOBE NEWSWIRE) — Veeco Instruments Inc. (NASDAQ: VECO) today has updated its financial guidance for the fourth quarter and full year 2024. We expect revenue for the fourth quarter of 2024 between $175 to $185 million, compared to our prior guidance of $165 to $185 million. Full year 2024 revenue is now expected in the range of $710 to $720 million. GAAP diluted earnings per share for the fourth quarter of 2024 is expected to be between $0.09 and $0.28, compared to our prior guidance of $0.18 to $0.27, while Non-GAAP diluted earnings per share is expected between $0.36 to $0.44, compared to our prior guidance of $0.35 to $0.45. Full year 2024 GAAP diluted earnings per share is expected in the range of $1.07 to $1.26, while Non-GAAP diluted earnings per share is expected in the range of $1.69 to $1.76. Reflected...

IRVINE, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) — Lantronix Inc. (NASDAQ: LTRX), a global leader in IoT compute and connectivity IoT solutions, is proud to announce the appointment of Daniel Quant as head of the Industrial IoT (IIoT) Products and Business Line at Lantronix. Reporting directly to Lantronix’s chief strategy officer Mathi Gurusamy, Quant will play a pivotal role in driving Lantronix’s vision of integrating Artificial Intelligence into Industrial IoT devices to meet the increasing demand for Edge Intelligence in industrial and enterprise environments. Quant brings more than two decades of global leadership experience in Industrial IoT and advanced wireless communication technologies. He has a proven track record of driving market growth, developing groundbreaking products and forging strategic partnerships. Before joining...

MOUNTAIN VIEW, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) — Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of glaucoma and retinal diseases, today announced preliminary unaudited operational and financial results for the fourth quarter and full year ended December 28, 2024. Fourth Quarter 2024 ResultsThe Company’s strategic review remains ongoing with multiple parties Total revenue is expected to be between $12.6 million and $12.7 million compared to $12.5 million in the prior year quarter Sold 12,700 Cyclo G6® probes compared to 12,700 in the prior year quarter Sold 47 Cyclo G6 Glaucoma Laser Systems, compared to 35 in the prior year quarterFull Year 2024 ResultsTotal revenue is expected to be between $48.6 million and $48.7...